Adverum Biotechnologies (ADVM) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces ...
Adverum will sell the shares at a price per share of $1.20, representing a premium of approximately 20% to its stock’s 30-day volume-weighted average price, and the financing is expected to close on ...
Adverum Biotechnologies, Inc. ADVM announced that it has completed the investigational new drug (“IND”) amendment with the FDA to begin a mid-stage study on its gene therapy candidate, ADVM-022, for ...
Adverum Biotechnologies (ADVM) has been beaten down lately with too much selling pressure. While the stock has lost 24.4% over the past four weeks, there is light at the end of the tunnel as it is now ...
Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is exempt of filing insider holdings with ...
Adverum Biotechnologies Inc (NASDAQ:ADVM) released data from its ongoing LUNA Phase 2 trial for Ixo-vec in patients with wet age-related macular degeneration (AMD). The 26-week interim analysis was ...
Hedge funds and other investment firms run by legendary investors like Israel Englander and Ray Dalio are entrusted to manage billions of dollars of accredited investors’ money because they are ...
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million holdings threshold to file a report that shows their positions at the end of every quarter. Even ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results